ArticleProceedings of the National Academy of Sciences of the United States of America2019
Genomic correlates of clinical outcome in advanced prostate cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 959 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
959citing papers in PubMed, 1 pooled it
109.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
959 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,365 citations in OpenAlex.
- Aging and prostate health: meta-analytic insights into age-related prostatic disorders.Frontiers in oncology · 2026Pooled it
- Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials.JCO precision oncology · 2026Trial
- Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial.JCO precision oncology · 2026Trial
- Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01.Future oncology (London, England) · 2026Trial
- Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial.Nature medicine · 2025Trial
- Programmed death-1 inhibition increases vaccine-induced T-cell infiltration in patients with prostate cancer.Journal for immunotherapy of cancer · 2025Trial
- Web-based application of integrated clinico-genomic prognostic nomograms in metastatic castration-resistant prostate cancer.The journal of liquid biopsy · 2026Article
- Genomic and transcriptomic correlates of deep prostate-specific antigen response in patients with metastatic androgen pathway modulation-sensitive prostate cancer.The oncologist · 2026Article
- Decoding the metabolic‑immune crosstalk: The role of glutamine and ammonium reprogramming in prostate cancer immune evasion (Review).Oncology reports · 2026Review
- Impact of BRCA Alterations on Androgen Receptor Pathway Inhibition Treatment Outcomes in Advanced Prostate Cancer.Cancer research communications · 2026Article
- Targeting the Fatty Acid Binding Protein 5-Specificity Protein 1 Axis Restores Enzalutamide Sensitivity by Suppressing Androgen Receptor/Androgen Receptor Splice Variant 7 Signaling: Implications for Prostate Cancer Therapy.World journal of oncology · 2026Article
- IRE1 activity is prognostic in localised and metastatic prostate cancer and affects epithelial lineage states.EMBO molecular medicine · 2026Article
- Temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggest a window of opportunity for checkpoint inhibitor therapy in prostate cancer.Journal for immunotherapy of cancer · 2026Article
- Combined BET bromodomain and DNA methyltransferase inhibition targets critical survival pathways in transdifferentiated prostate cancer.JCI insight · 2026Article
- Dual Functions of B7-H3-MAPK Signaling Orchestrate Tumor Immunosuppression via Regulating the Plasticity of Myeloid-derived Suppressor Cells and Fibroblasts.Cancer discovery · 2026Article
- Identification of Novel Transcriptional Alleles in Primary Prostate Cancer Cells and Cancer Stem Cells by Bulk RNA-Seq and Single-Cell RNA-Seq Analyses.Biomolecules · 2026Article
- Tumor-derived CTHRC1 mediates ITGB3-dependent osteoclast differentiation to promote prostate cancer bone metastasis.Oncogene · 2026Article
- Commensal Nakaseomyces glabratus migrates into prostate tumors to accelerate cancer progression.Nature cancer · 2026Article
- The RNA cargo of plasma-derived extracellular vesicles in mCRPC patients captures cancer cells and tumor microenvironment signals.bioRxiv : the preprint server for biology · 2026Article
899 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
43 authors at 12 institutions in 4 countries.
Wassim AbidaDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Joanna CyrtaDepartment of Pathology, Weill Medical College of Cornell University, New York, NY 10021.
Glenn HellerDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Davide PrandiDepartment of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, 38123 Trento, Italy.
Joshua ArmeniaHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Ilsa ColemanFred Hutchinson Cancer Center, University of Washington, Seattle, WA 98109.
Marcin CieslikDepartment of Pathology, University of Michigan, Ann Arbor, MI 48109.
Matteo BenelliDepartment of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, 38123 Trento, Italy.
Dan RobinsonDepartment of Pathology, University of Michigan, Ann Arbor, MI 48109.
Eliezer M Van AllenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.
Andrea SbonerDepartment of Pathology, Weill Medical College of Cornell University, New York, NY 10021.
Tarcisio FedrizziDepartment of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, 38123 Trento, Italy.
Juan Miguel MosqueraDepartment of Pathology, Weill Medical College of Cornell University, New York, NY 10021.
Brian D RobinsonDepartment of Pathology, Weill Medical College of Cornell University, New York, NY 10021.
Navonil De SarkarFred Hutchinson Cancer Center, University of Washington, Seattle, WA 98109.
Lakshmi P KunjuDepartment of Pathology, University of Michigan, Ann Arbor, MI 48109.
Scott TomlinsDepartment of Pathology, University of Michigan, Ann Arbor, MI 48109.
Yi Mi WuDepartment of Pathology, University of Michigan, Ann Arbor, MI 48109.
Daniel Nava RodriguesInstitute of Cancer Research, London SW7 3RP, United Kingdom.
Massimo LodaDepartment of Pathology, Weill Medical College of Cornell University, New York, NY 10021.
Anuradha GopalanDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Victor E ReuterDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Colin C PritchardFred Hutchinson Cancer Center, University of Washington, Seattle, WA 98109.
Joaquin MateoInstitute of Cancer Research, London SW7 3RP, United Kingdom.
Diletta BianchiniInstitute of Cancer Research, London SW7 3RP, United Kingdom.
Susana MirandaInstitute of Cancer Research, London SW7 3RP, United Kingdom.
Suzanne CarreiraInstitute of Cancer Research, London SW7 3RP, United Kingdom.
Pasquale RescignoInstitute of Cancer Research, London SW7 3RP, United Kingdom.
Julie FilipenkoProstate Cancer Clinical Trials Consortium, New York, NY 10065.
Jacob VinsonProstate Cancer Clinical Trials Consortium, New York, NY 10065.
Robert B MontgomeryFred Hutchinson Cancer Center, University of Washington, Seattle, WA 98109.
Himisha BeltranDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.
Elisabeth I HeathDepartment of Pathology, Wayne State University School of Medicine, Detroit, MI 48201.
Howard I ScherDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Philip W KantoffDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Mary-Ellen TaplinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.
Nikolaus SchultzDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Johann S deBonoInstitute of Cancer Research, London SW7 3RP, United Kingdom.
Francesca DemichelisDepartment of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, 38123 Trento, Italy.
Peter S NelsonFred Hutchinson Cancer Center, University of Washington, Seattle, WA 98109; pnelson@fhcrc.org mark.rubin@dbmr.unibe.ch arul@med.umich.edu sawyersc@mskcc.org.
Mark A RubinDepartment of Pathology, Weill Medical College of Cornell University, New York, NY 10021; pnelson@fhcrc.org mark.rubin@dbmr.unibe.ch arul@med.umich.edu sawyersc@mskcc.org.
Arul M ChinnaiyanDepartment of Pathology, University of Michigan, Ann Arbor, MI 48109; pnelson@fhcrc.org mark.rubin@dbmr.unibe.ch arul@med.umich.edu sawyersc@mskcc.org.
Charles L SawyersHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065; pnelson@fhcrc.org mark.rubin@dbmr.unibe.ch arul@med.umich.edu sawyersc@mskcc.org.ORCID 0000-0003-4955-6475
Memorial Sloan Kettering Cancer Center · USNational Health Service · GBCornell University · USUniversity of Michigan · USUniversity of Washington · USUniversity of Trento · ITCancer Clinic · USUniversity of Bern · CHBroad Institute · USDana-Farber Cancer Institute · USHoward Hughes Medical Institute · USWayne State University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MSPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Yu Chen, MICHAEL J MORRIS · 2001 to 2026
$63.0MTRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI John Kyung Lee · 2002 to 2026
$58.1MTumor and Circulating Markers as Links Between Obesity and Lethal Prostate CanceP50CA090381 · NCI · DANA-FARBER CANCER INSTITUTE · PI LODA, MASSIMO · 2002 to 2017
$36.2MTissue/InformaticsP50CA186786 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Robert Timothy Dess · 2014 to 2026
$27.6MWeill Cornell Medicine (WCM) SPORE in Prostate CancerP50CA211024 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI GUDAS, LORRAINE J · 2017 to 2021
$10.9MThe MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity CenterU54CA224079 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2017 to 2021
$6.8MUnderstanding Resistance to Next Generation AntiandrogensR01CA155169 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2012 to 2022
$3.8MTowards Understanding Prostate Cancer HeterogeneityR01CA125612 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI RUBIN, MARK A. · 2007 to 2017
$3.4MFHCRC High-Performance Computing ClusterS10OD020069 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KOOPERBERG, CHARLES L · 2015 to 2015
$600kCancer Research UKDepartment of HealthNCI NIH HHS P30 CA008748NCI NIH HHS P50 CA090381NCI NIH HHS P50 CA092629NCI NIH HHS P50 CA097186NCI NIH HHS P50 CA186786NCI NIH HHS P50 CA211024NCI NIH HHS R01 CA125612NCI NIH HHS R01 CA155169NCI NIH HHS U54 CA224079NIH HHS S10 OD020069
Abstract
Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent through several comprehensive profiling efforts, but little is known about the impact of this heterogeneity on clinical outcome. Here, we report comprehensive genomic and transcriptomic analysis of 429 patients with metastatic castration-resistant prostate cancer (mCRPC) linked with longitudinal clinical outcomes, integrating findings from whole-exome, transcriptome, and histologic analysis. For 128 patients treated with a first-line next-generation androgen receptor signaling inhibitor (ARSI; abiraterone or enzalutamide), we examined the association of 18 recurrent DNA- and RNA-based genomic alterations, including androgen receptor (
Indexed as
AgedAndrostenesBenzamidesBiomarkers, TumorDrug Resistance, NeoplasmGenomicsHumansMaleMiddle AgedNitrilesPhenylthiohydantoinProstatic Neoplasms, Castration-ResistantReceptors, AndrogenTreatment OutcomeabirateroneAndrostenesBenzamidesBiomarkers, TumorenzalutamideNitrilesPhenylthiohydantoinReceptors, Androgenbiomarkerscastration-resistant prostate cancerclinical outcomesintegrative genomics
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.